ArticleScientific reports2025
Antimalarial potential of curcumin derivatives evaluated through experimental and computational approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Malaria remains a leading global health threat, with cases and deaths continually increasing each year. The rising number of drug-resistant cases further diminishes the effectiveness of current antimalarials, highlighting the need for potent and effective new compounds. Curcumin, a natural polyphenol, has been extensively studied for its therapeutic properties. However, its clinical use is limited by poor bioavailability. This study evaluates curcumin derivatives as potential antimalarial agents through in-silico screening and biological assessments, aiming to identify promising candidates for further development. For the first time, we reveal the multi-target mechanisms of action of these derivatives, focusing on their potential for immunomodulatory GSK-3β inhibition and haemin binding. The ten synthesised compounds, which include Knoevenagel condensates, heterocyclic pyrazoles, and monocarbonyl derivatives, show favourable GSK-3β binding and improved specific ADMET parameters compared to curcumin, along with favourable electronic and reactivity profiles. These compounds also demonstrate greater potency than curcumin against both P. falciparum CQ-sensitive 3D7 and multidrug-resistant K1 strains. Notably, monocarbonyl derivative 20 exhibited the most potent EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.